BioLife Solutions, Inc. (BLFS)

Market Cap	1.21B +17.2%
Revenue (ttm)	101.66M +29.9%
Net Income	-2.96M
EPS	-0.07
Shares Out	48.86M
PE Ratio	n/a
Forward PE	109.13
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,073,798
Open	23.80
Previous Close	24.00
Day's Range	23.59 - 24.77
52-Week Range	17.86 - 29.62
Beta	1.97
Analysts	Strong Buy
Price Target	32.30 (+30.56%)
Earnings Date	May 7, 2026

About BLFS

BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduc...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• IPO Date: Nov 22, 1989
• Employees: 155
• Stock Exchange: NASDAQ
• Ticker Symbol: BLFS
• Website: https://www.biolifesolutions.com

Financial Performance

In 2025, BioLife Solutions's revenue was $96.21 million, an increase of 28.89% compared to the previous year's $74.65 million. Losses were -$4.60 million, -77.23% less than in 2024.

Analyst Summary

According to 10 analysts, the average rating for BLFS stock is "Strong Buy." The 12-month stock price target is $32.3, which is an increase of 30.56% from the latest price.

Price Target

$32.3

(30.56% upside)

Analyst Consensus: Strong Buy